The importance of biologics in today’s drug development market is evident from the statistics. As the number of biologics going off patent increases, biosimilar medicines promise to be an attractive offering to healthcare organisations, physicians and patients by providing greater choice and a more cost effective alternative.
38+Biosimilar studies including early phase and phase III
ICON provides clients with a fully integrated approach to the development of biosimilars. We can help you to choose the right target molecule and the optimal development and commercial strategy. Our experts have the insight needed in drug development, regulatory conditions and commercialisation along with the operational capability to deliver your programmes on time and within budget.
- 药物开发咨询: We have a strong track record in strategically advising clients through the development continuum.
- 早期服务与临床药理学: ICON specialises in the strategy and delivery of early-phase clinical development services to enable informed, timely decision making for our clients.
- III期临床研究服务: We provide clients with a flexible, best-in-class approach to improve cycle times, constrain costs and reduce risks.
- Bioanalytical Laboratories: ICON provides a full range of laboratory services that are dedicated exclusively to clinical development.
- Value Access and Outcomes：集成市场准入，定价，通信和健康经济专家提供战略指导和战术解决方案，以展示您的产品价值，并支持全球的品牌成功。